Hypertrophic Cardiomyopathy
Conditions
Keywords
Echocardiography, hypertrophic cardiomyopathy, cardiomyopathy, magnetic resonance imaging, contrast
Brief summary
Assessment of wall thickness in hypertrophic cardiomyopathy (HCM) is of diagnostic and prognostic importance given its known association with sudden cardiac death. However, data regarding comparison of imaging modalities for this key measurement is lacking. This study seeks to compare assessment of maximum wall thickness between clinically indicated echocardiography (with and without contrast) and clinically indicated cardiac magnetic resonance imaging.
Detailed description
Patients receiving clinically indicated echocardiograms and cardiac magnetic resonance imaging at Mayo Clinic will be eligible.
Interventions
PROCEDURENoncontrast echocardiography
PROCEDUREContrast Echocardiography
PROCEDURECardiac magnetic resonance imaging
Sponsors
GE Healthcare
Mayo Clinic
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Clinically and echocardiographically defined hypertrophic cardiomyopathy. 2. Clinically indicated transthoracic echocardiography as part of the medical evaluation. 3. No contradiction to administration of ultrasonic echocardiography contrast. 4. Planned clinically indicated cardiac magnetic resonance imaging as part of medical evaluation. 5. No contraindication to cardiac magnetic resonance imaging (such as cochlear implants, central nervous system aneurysm clips and other implanted medical devices). 6. Age 18 years and older
Exclusion criteria
1\) Insufficient image quality for determination of maximal wall thickness.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Left Ventricular Wall Thickness | approximately 1 week after enrollment | All subjects will undergo noncontrast echocardiography, contrast echocardiography and cardiac MRI. |
Countries
United States
Outcome results
None listed